EVAX
xA9; Evaxion Biotech A/S. All rights reserved worldwide. Copenhagen, Denmark, 2022. Anticipated Key Milestones 2022-23 2 AI Platform Indication Product Candidate Phase 2022 2023 2024 PIONEER Immuno-oncology Metastatic Me
Friday, July 1, 2022 BiopharmaWatch Research 1 min read Key Takeaway: Aureus EVX-B1 Pre-clinical H2 Regulatory filing Phase 1/2 EDEN Infectious diseases N. Gonorrhoeae EVX-B2 Pre-clinical H1 Selection of second bacterial target Partnership RAVEN Infectious diseases EVX-V1 Pre-clinical H2 Selection of first viral product candidate Partnership
Price reaction · baseline $96 (2022-06-30 close) · hit after-hours · clean, no other EVAX news in the window
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+17%
120-day peak, hindsight
Typical move
14.2%
average across 4 past catalysts
Lead asset
EVX-01
Phase 2 · Melanoma Stage IV
Full Press Release Details
Aureus EVX-B1 Pre-clinical H2 Regulatory filing Phase 1/2 EDEN Infectious diseases N. Gonorrhoeae EVX-B2 Pre-clinical H1 Selection of second bacterial target Partnership RAVEN Infectious diseases EVX-V1 Pre-clinical H2 Selection of first viral product candidate Partnership